VimpelCom Ltd. (NASDAQ:VIP) shares advanced 6.25% in last trading session and ended the day at $3.57. VIP Gross Margin is 75.20% and its has a return on assets of -1.20%. VimpelCom Ltd. (NASDAQ:VIP) quarterly performance is -37.04%.
VimpelCom (NASDAQ:VIP) announced a quarterly dividend on Friday, November 6th. Investors of record on Monday, November 23rd will be given a dividend of 0.035 per share on Monday, December 7th. This represents a $0.14 annualized dividend and a dividend yield of 3.98%.
Kirby Corporation (NYSE:KEX) ended the last trading day at $65.64. Company weekly volatility is calculated as 2.31% and price to cash ratio as 1418.09. Kirby Corporation (NYSE:KEX) showed a weekly performance of -1.87%.
Kirby Corporation (“Kirby”) (NYSE: KEX) announced net earnings attributable to Kirby for the third quarter ended September 30, 2015 of $56.8 million, or $1.04 per share, compared with $76.7 million, or $1.34 per share, for the 2014 third quarter. Consolidated revenues for the 2015 third quarter were $532.6 million compared with $680.7 millionfor the 2014 third quarter.
On 10 November, Health Insurance Innovations, Inc. (NASDAQ:HIIQ) shares advanced 6.00% and was closed at $4.59. HIIQ EPS growth in last 5 year was 0.00%. Health Insurance Innovations, Inc. (NASDAQ:HIIQ) year to date (YTD) performance is -35.89%.
Health Insurance Innovations (NASDAQ: HIIQ) reported Q3 EPS of $0.08, $0.04 better than the analyst estimate of $0.04. Revenue for the quarter came in at $25.8 million versus the consensus estimate of $27.67 million. The company also announced that Patrick McNamee has been named Chief Executive Officer and a member of the Board of Directors of Health Insurance Innovations Inc., effective immediately.
Sophiris Bio, Inc. (NASDAQ:SPHS) shares advanced 236.70% in last trading session and ended the day at $2.90. And its has a return on assets of -92.40%. Sophiris Bio, Inc. (NASDAQ:SPHS) quarterly performance is 202.08%.
Sophiris Bio Inc. (NASDAQ: SPHS) announced final results from its Phase 3 “PLUS-1” study of PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). PRX302 demonstrated a statistically significant improvement in International Prostate Symptom Score (IPSS) total score from baseline over 12 months compared to the vehicle-only control group (7.60 vs. 6.58 point overall improvement; p = 0.043), the primary endpoint of the study. PRX302 continues to demonstrate a favorable safety profile, with no evidence of any treatment related sexual or cardiovascular side effects.
Plug Power Inc. (NASDAQ:PLUG) caters to the Technology space. It has a net profit margin of -49.30% and weekly performance is -33.62%. On the last day of trading company shares ended up at $1.90. Plug Power Inc. (NASDAQ:PLUG) distance from 50-day simple moving average (SMA50) is 3.84%.
Plug Power Inc. (NASDAQ:PLUG) has taken even further steps toward achieving its 2015 objectives with its third quarter results, recording a year-on-year total revenue increase of 58% for the period.The company recorded revenue of $31.4m in third quarter 2015, and bookings that exceeded $50m. It attributed the strong increase in total revenues as being driven by more GenDrive units sold, hydrogen infrastructure installation sales associated with seven sites in service revenues in 2015, and increased GenCare service revenues.
Plug Power recognised revenue for more than 1,200 units in the third quarter, and now has more than 9,000 units in the field.
Leave a Reply